When a cancer patient and his or her doctor discuss the value of a treatment option, the conversation usually centers on a consideration of the treatment's medical benefits versus its possible side effects for the patient.
Increasingly, however, as the already high costs of cancer care continue to rise, a full view of the patient's welfare must also take into account the economic impact of the treatment on the patient and his or her family.
Additionally, beyond its clear impact on patients, the increasing cost of cancer care also presents challenges to other stakeholders involved in the development and delivery of care.
"Cancer care is one of the most expensive areas of health care today, and the cost of that care is increasing steadily, for patients and for society as a whole," says Neal J. Meropol, M.D., director of the gastrointestinal cancer and gastrointestinal tumor risk assessment programs at Fox Chase Cancer Center. Meropol, who is also a member of the American Society of Clinical Oncology (ASCO) Cost of Care Task Force and lead author on the upcoming ASCO Guidance Statement on the Cost of Cancer Care, offered his analysis of the problem in a talk presented at the ASCO annual meeting in Orlando today.
"As physicians, we have a responsibility to understand the impact that the increasing cost of cancer care has on everyone involved," Meropol notes. "In particular, we need to be able to discuss with our patients the impact that high out-of-pocket expenses might have on them and their families, however difficult that conversation might be. More and more, cost considerations have an appropriate role in the assessment of treatment options."
According to Meropol, other stakeholders affected by the rising cost of cancer care in addition to patients include employers who must remain competitive while subsidizing their employees' health care, health insurance providers who must watch their bottom lines while deciding which treatments to pay for and at what level, physicians who must offer guidance for their patients in choosing among treatments, including new drugs that might offer modest survival benefits but at significant additional cost, and the pharmaceutical industry, which hopes to earn a profit from the sale of innovative drugs that can cost $1 billion to research and develop.
Meropol observes that many of the costly new cancer drugs now coming to market are highly targeted in their action, often quite effective but only in a subset of patients. While these drugs anticipate the dream of personalized medicine, their high costs must be shared over a smaller potential pool of patients, perhaps threatening the future of this promising new direction in medicine.
Rising costs also have the potential to widen the disparities that already exist in cancer outcomes among different populations, adding an ethical dimension to the problem.
"Rising costs may be a key impediment to reaching our societal goal of providing high quality cancer care to all citizens," Meropol says. Going forward, the challenges in confronting the cost-of-cancer-care issue are substantial. Patients and their physicians both feel ill-equipped to consider treatment costs in the clinical setting, and society has yet to address this multifaceted issue in a comprehensive way. Still, Meropol says, we have no alternative but to begin the search for answers now. The increasing economic burden posed by cancer-care costs on patients and their families – and on society – is too great to ignore.
Fox Chase Cancer Center is one of the leading cancer research and treatments centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach.Education Session:
Frank Hoke | EurekAlert!
Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
20.10.2017 | Information Technology
20.10.2017 | Materials Sciences
20.10.2017 | Interdisciplinary Research